Kestra Medical Technologies (NASDAQ:KMTS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Kestra Medical Technologies Trading Down 3.0%

KMTS opened at $29.69 on Friday. The firm has a market cap of $1.77 billion, a P/E ratio of -11.12 and a beta of 0.51. Kestra Medical Technologies has a 12 month low of $17.34 and a 12 month high of $31.06. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average of $26.69 and a 200 day moving average of $23.82.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million for the quarter. As a group, research analysts forecast that Kestra Medical Technologies will post -2.45 EPS for the current year.

Insider Activity

In other news, CFO Vaseem Mahboob sold 4,788 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $30.60, for a total transaction of $146,512.80. Following the transaction, the chief financial officer directly owned 60,609 shares of the company’s stock, valued at approximately $1,854,635.40. This trade represents a 7.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Raymond W. Cohen sold 3,330 shares of Kestra Medical Technologies stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total transaction of $97,502.40. Following the sale, the director directly owned 54,790 shares of the company’s stock, valued at $1,604,251.20. This represents a 5.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 399,694 shares of company stock valued at $10,842,727. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sei Investments Co. raised its position in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the period. Corient Private Wealth LP grew its position in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after buying an additional 44,839 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after buying an additional 22,471 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies during the first quarter valued at $603,000.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.